XOMA Corporation (NASDAQ:XOMA) Rating Changes as of May 17, 2018

May 17, 2018 - By Vernon Rice

XOMA Corporation (NASDAQ:XOMA) Corporate Logo

XOMA Corporation (NASDAQ:XOMA) Ratings Coverage

In total 2 analysts cover Xoma Corp (NASDAQ:XOMA). “Buy” rating has 2, “Sell” are 0, while 0 are “Hold”. (NASDAQ:XOMA) has 100% bullish analysts. 6 are the (NASDAQ:XOMA)’s ratings reports on May 17, 2018 according to StockzIntelligence Inc. The company rating was maintained by H.C. Wainwright on Monday, April 30. On Friday, March 9 the stock of XOMA Corporation (NASDAQ:XOMA) earned “Buy” rating by H.C. Wainwright. In Tuesday, February 6 report Wedbush maintained the stock with “Buy” rating. On Thursday, January 18 the stock has “Buy” rating by H.C. Wainwright. The stock rating was maintained by H.C. Wainwright with “Buy” on Thursday, December 7. On Tuesday, December 19 the rating was maintained by Wedbush with “Buy”. Listed here are XOMA Corporation (NASDAQ:XOMA) PTs and latest ratings.

30/04/2018 Broker: H.C. Wainwright Rating: Buy New Target: $49.0000 Maintain
09/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $49.0 Maintain
06/02/2018 Broker: Wedbush Rating: Buy New Target: $33.0 Maintain
18/01/2018 Broker: H.C. Wainwright Rating: Buy New Target: $49.0 Maintain
19/12/2017 Broker: Wedbush Rating: Buy New Target: $33.0 Maintain
07/12/2017 Broker: H.C. Wainwright Rating: Buy New Target: $38.0 Maintain

The stock decreased 2.69% or $0.68 during the last trading session, reaching $24.6.XOMA Corporation has volume of 72,030 shares. Since May 17, 2017 XOMA has risen 184.45% and is uptrending. The stock outperformed the S&P 500 by 172.90%.

XOMA Corporation discovers, develops, and commercializes antibody therapeutics in the United States, Europe, and the Asia Pacific.The firm is worth $205.83 million. The companyÂ’s product candidates include X358, a human negative allosteric modulating insulin receptor antibody that is in Phase II proof-of-concept study for the treatment of patients with hypoglycemia due to congenital hyperinsulinism and hypoglycemia in post-bariatric surgery patients; X213, a allosteric inhibitor for the treatment of prolactinoma and anti-psychotic-induced hyperprolactinemia; and X129, a potent fragment of a monoclonal antibody for the treatment of patients with acute severe hypoglycemia.11.2 is the P/E ratio. The Company’s preclinical product candidates comprise interleukin 2 for the treatment of metastatic melanoma and renal cell carcinoma; and anti-parathyroid receptor, a G-protein-coupled receptor for the treatment of hyperparathyroidism and humoral hypercalcemia of malignancy.

Another two news for XOMA Corporation (NASDAQ:XOMA) were briefly released by: Nasdaq.com on May 09, 2018 with title “XOMA Reports First Quarter 2018 Financial Results”. The other Globenewswire.com‘s article was titled “New Research: Key Drivers of Growth for HTG Molecular Diagnostics, Impinj, XOMA, Stock Yards, TriCo Bancshares …” and released on May 02, 2018.

XOMA Corporation (NASDAQ:XOMA) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.